UB104 is an innovative EGF formula explored by the Group in cooperation with the NAMI.
UB104 is indicated for treating skin wound infection after surgery or accidental injury. Compared with traditional gauze wound dressings, UB104 can promote wound healing more quickly, and the operation is more convenient and controllable.
UB104 has good biocompatibility and antibacterial activity, and greatly accelerates the wound healing process and reduces scarring.
Ease of use, precise dosage, and less pain when changing dressings.
Excellent breathability, antibacterial, and properties with high stability and long lasting.
According to the Fortune Business Insights, the global wound care market size is expected to gain momentum by reaching USD 24.01 billion by 2028 while exhibiting a CAGR of 6.1% between 2021 and 2028.
China's aging population, improved medical standards, and rising income provide an upside for the market of medical dressing. It is predicted that the market size of China dressings industry will maintain a CAGR of 11.1% between 2019 and 2023, and the market size will reach 23.45 billion RMB in 2023.
Nano dressings belong to the high-end category. According to QYResearch, the global high-end dressing market is expected to reach USD 7.23 billion by 2027.
